Brainomix's e-Lung AI Software Receives FDA Clearance

17 May 2024

Brainomix proudly announces the FDA clearance of its latest product, Brainomix 360 e-Lung, a groundbreaking AI imaging solution for precision medicine.

This marks Brainomix's expansion into lung imaging following the successful adoption of its Brainomix 360 Stroke platform in the US and Europe.

The clearance of e-Lung is a significant milestone for Brainomix, representing a step forward in advanced lung imaging solutions. With a rich academic heritage and a focus on scientific excellence, Brainomix plans to deepen its research collaborations in pulmonology to continually improve e-Lung.

The University of Chicago Medicine expressed excitement about Brainomix's venture into lung imaging and its potential to enhance healthcare delivery for patients with lung disease.

Recently, Brainomix published a study in collaboration with AstraZeneca in the American Journal of Respiratory and Critical Care Medicine, demonstrating the effectiveness of its lung imaging biomarkers in stratifying patients at risk of Idiopathic Pulmonary Fibrosis (IPF) progression.

CEO and Co-Founder of Brainomix, emphasized the company's commitment to developing innovative solutions that empower healthcare professionals and improve patient outcomes.

Brainomix will present its latest e-Lung data at the American Thoracic Society (ATS) annual conference, showcasing collaborations with Heidelberg University and Avalyn Pharma.